Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE trial

The goal of the trial was to evaluate empagliflozin compared with placebo among patients with acute decompensated heart failure. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has been shown to reduce the risk of cardiovascular death or heart failure hospitalization among patients with chronic heart failure. 530 participants with acute heart failure were randomized to empagliflozin 10 mg daily versus placebo. Their mean age was 71 years, 47% were diabetics, and were followed for 90 days. The participants had N-terminal pro–B-type natriuretic peptide (NT-proBNP) ≥1600 pg/ml or BNP ≥400 pg/ml during hospitalization or within 72 hours prior to admission, and the median left ventricular ejection fraction was 31% The primary analysis showed that among patients with acute decompensated heart failure, empagliflozin versus placebo was associated with significant clinical benefit at 90 days Empagliflozin versus placebo was also associated with fewer deaths, improvement in quality of life, and greater reduction in body weight. Thus The EMPULSE trial showed that empagliflozin was beneficial at reducing adverse events among acute decompensated heart failure patients Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.